378 related articles for article (PubMed ID: 35053602)
1. Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
Martori C; Sanchez-Moral L; Paul T; Pardo JC; Font A; Ruiz de Porras V; Sarrias MR
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053602
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
Chyuan IT; Chu CL; Hsu PN
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
[TBL] [Abstract][Full Text] [Related]
3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
4. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
5. Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer.
Yang F; Li J; Ge Q; Zhang Y; Zhang M; Zhou J; Wang H; Du J; Gao S; Liang C; Meng J
Biochem Pharmacol; 2023 Aug; 214():115669. PubMed ID: 37364622
[TBL] [Abstract][Full Text] [Related]
6. Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer.
Ollivier L; Labbé M; Fradin D; Potiron V; Supiot S
Front Oncol; 2021; 11():744679. PubMed ID: 34595122
[TBL] [Abstract][Full Text] [Related]
7. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
Leong A; Kim M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
[TBL] [Abstract][Full Text] [Related]
8. The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy.
Kwon M; Jung H; Nam GH; Kim IS
J Control Release; 2021 Mar; 331():321-334. PubMed ID: 33434599
[TBL] [Abstract][Full Text] [Related]
9. Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction.
Guo J; Zhao J; Sun L; Yang C
Front Oncol; 2022; 12():955718. PubMed ID: 35924159
[TBL] [Abstract][Full Text] [Related]
10. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S; Wesolowski R; Gatti-Mays ME
Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
Bansal D; Reimers MA; Knoche EM; Pachynski RK
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477569
[TBL] [Abstract][Full Text] [Related]
12. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-based immunotherapy of pancreatic cancer.
Noubissi Nzeteu GA; Gibbs BF; Kotnik N; Troja A; Bockhorn M; Meyer NH
Front Mol Biosci; 2022; 9():948898. PubMed ID: 36106025
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment.
Mahmood J; Shukla HD; Soman S; Samanta S; Singh P; Kamlapurkar S; Saeed A; Amin NP; Vujaskovic Z
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30486519
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Giannone G; Ghisoni E; Genta S; Scotto G; Tuninetti V; Turinetto M; Valabrega G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575899
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.
Wang I; Song L; Wang BY; Rezazadeh Kalebasty A; Uchio E; Zi X
Am J Clin Exp Urol; 2022; 10(4):210-233. PubMed ID: 36051616
[TBL] [Abstract][Full Text] [Related]
17. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.
Wang B; Zhao Q; Zhang Y; Liu Z; Zheng Z; Liu S; Meng L; Xin Y; Jiang X
J Exp Clin Cancer Res; 2021 Jan; 40(1):24. PubMed ID: 33422072
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
[TBL] [Abstract][Full Text] [Related]
19. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
20. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
